5th MERIDIANTECH-COVID19 Workshop

Bioelectrical Diagnostics & Coherent Therapy

"COVID-19 clinical study protocols, Details of the PROGNOS® System & demonstration of PROGNOS® ViralExpress®"

Saturday 09 May 17:00 Central European Summer Time

Hosted by
MEDPREVENT systems GmbH & Co. KG DE

Spaces limited to 20 participants

To participate in the workshop and further information register at:

madan.thangavelu4@gmail.com

Mobile & WhatsApp: + 44 7830 300 728

5th MERIDIANTECH-COVID19 Workshop
Bioelectrical Diagnostics & Coherent Therapy
"COVID-19 Multicentric International Trials for Diagnosis-driven Personalised Precision Therapy"

Saturday 09 May 17:00 CEST – Hosted by MEDPREVENT systems GmbH & Co. KG DE

Giulio **TARRO :**   http://www.giuliotarro.it/ , https://twitter.com/TarroGiulio & https://it.wikipedia.org/wiki/Giulio_Tarro:
Past, present and the future of human viral diseases

Vincenzo **VALENZI** MD www.cimb.me , Patrizio **CARRA**i Chemistry Pisa University,Pasquale **AVINO** Chemistry Molise Univeristy
Intermolecule signalling: Subtle molecular signals and their role in regulation of inflammation

Dr. med Michael **BAUER,** Raimund **HOFFMAN &** Franziska **MICHL**: *MEDPREVENTsystems GmbH, Marktredwitz, Germany*
PROGNOS system and Viral Express: Operating the PROGNOS System and overview of viral testing

Luca **GAMBERALE & Milly MORATTI:** *LEDA/Bicocca Research Center for Innovative Research in Applied Physics*
Quantum Theory in Biology and applications in medicine

Habib **DOUAGUI:**   *Professor & Head, Department of Pneumo-allergology, Center Hospitalo Universitaire de Béni Messous, Algiers, Alger*
The current state of COVID-19 treatment in Africa: Perspectives and the need for personalized, precision therapy

Judu **ILAVARASU:**   *Division of Yoga and Physical Sciences, Swami Vivekananda Yoga Anusandhana Samsthana (SVYASA),Bangalore, India*
SVYASA: Priorities for a meridian energy research project in S-VYASA, Bangalore

Dmitriy **Taranenko :**   **ALTIMED,** Kiev, *https://www.altimed.net/en/*:
ALTIMED Device for electromagnetic contrast to COVID-19, mechanism of action and preliminary results
, Madan **THANGAVELU** www.iiimb.me
PROGNOSNET COVID-19: Organization of the Network, Clinical Studies and Study protocols & Project Timelines

MERIDIANTECH: COVID 19

1 Diagnostics: Bioelectrical status of meridians and organ function (large intestine and lung meridians)

2: Diagnostics-driven treatment: Clinical trials for rebalancing and boosting bioelectrical status & predictive-personalised treatments

Stratification of population for grades of health, wellbeing & clinical frailty

age ♂ ♀

20-29
30-39
40-49
50-59
60-69
70+

Daily monitoring

Healthy / Asymptomatic	Pre-symptomatic , Suspected COVID-19	COVID-19 positive	Remission
1	2	Stage 1 Stage 2 Stage 3 — 3	4

Prognos Prophylaxis

Prognos Treat. #1
Antiviral

Prognos Treat.#2
Antiviral + Antiinflamma

Prognos Treat.#3

Prognos Treat.#4

Prognos Boost

♂ ♀ **age**

< 40
40-49
50-59
60-69
70+

Daily monitoring

1: Asymptomatic / Healthy: for baseline and grades of health, ages 20 to 70+, males & females
Prophylaxis: Bioelectrical status monitoring for personalised dietary & nutritional supplements

2: Pre-symptomatic , symptomatic, suspected COVID-19, requires testing
Treatment No.1: Antiviral, gastroprotectant, ??

3: Confirmed COVID-19: Predictive-Personalised Treatment
Stage 1;Initial management outside of critical care **Treatment No. 2: Antiviral + Antiinflammatory??**
Stage 2 tending towards critical care (**Treatment No. 3: ???**
Stage 3: in critical care, (**Treatment No.4: ???**

4: **In remission**: Bioelectrical status monitoring for personalised dietary nutritional supplements for rebalancing

NICE UK Critical care referral algorithm to support decision making.

Allegato 1. Percorsi assistenziali e terapeutici per pazienti COVID-19.

(1) PS →

TAMPONE
EGA
TC TORACE
VALUTAZIONE FR

ESAMI EMATOCHIMICI
(pannello COVID)

→ Eupnoico
Negatività radiologica
EGA nella norma
Walking-test negativo

→ Se Paziente positivo per COVI-19 asintomatico o con sintomi lievi (Febbre (≤37,5°C), tosse, sintomi da raffreddamento senza dispnea), età < 70 anni e senza fattori di rischio (BPCO, diabete e cardiopatia) e TC torace negativo

→ **DIMISSIONE AL DOMICILIO**
terapia dei sintomi (paracetamolo, idratazione, riposo, adeguato introito calorico) e **monitoraggio con saturimetro e relativa app.** Sconsigliata assunzione di farmaci senza indicazione medica.

→ **DIMISSIONE A STRUTTURE RESIDENZIALI**
terapia dei sintomi (paracetamolo, idratazione, riposo, adeguato introito calorico) **monitoraggio con saturimetro e relativa app.** Sconsigliata assunzione di farmaci senza indicazione medica.

(2) Malattie Infettive (priorità) / Reparto COVID bassa intensità(IV piano) ←

Caso positivo confermato e O2 terapia bassi flussi →

Paziente positivo per COVI-19 con sintomi respiratori lievi ma di età > 70 anni e/o con fattori di rischio (BPCO, diabete e cardiopatia) oppure sintomatico o con sintomi lievi (Febbre (>37,5°C), tosse, dispnea da lieve a moderata) TC/torace con quadro di polmonite:

- idrossiclorochina cp 200 mg, 1 x 2 oppure x3/die se non disponibile clorochina 500 mg, 1 x 2/ die. Durata della terapia: da 7 a 10 giorni, con timing da stabilire secondo evoluzione clinica (PS: se permanenza prevista oltre le 24 h inizia trattamento in PS). NB: Necessaria valutazione cardiologica ECG (valutazione QT) ****
- Rapido peggioramento clinico: richiedere Remdesivir ad uso compassionevole. Appena disponibile: Remdesivir fiale 150 mg: 1 giorno 200 mg ev in 30 minuti poi 100 mg ev /die per altri 9 giorni in associazione ad idrossiclorochina 200 mg, 1 x 2/die con timing da stabilire secondo evoluzione clinica. NB: Benché l'attuale evidenza scientifica non supporta l'uso di lopinavir/ritonavir o darunavir/cobicistat 800/150 mg 1 cp/die questi farmaci possono essere considerati nei singoli casi in fase precoce se non disponibile Remdesivir (Vedi anche nota AIFA 24/03/20).

peggioramento ↓ / miglioramento ↑

(3) Pneumologia / Medicina Fast ←

Ossigeno terapia
Frequenza respiratoria> 22 con >6L/minuto di O2
PaO2 <65mmHg con >6L/minuto di O2
Rivalutazione dei casi in rapido peggioramento clinico con anestetista/rianimatore dedicato →

- idrossiclorochina cp 200 mg, 1 x 2 oppure x3/die se non disponibile clorochina 500 mg, 1 x 2/ die. Durata della terapia: da 7 a 10 giorni, con timing da stabilire secondo evoluzione clinica NB: Necessaria valutazione cardiologica ECG (valutazione QT) ****
Richiedere Remdesivir ad uso compassionevole. Appena disponibile: Remdesivir fiale 150 mg: 1 giorno 200 mg ev in 30 minuti poi 100 mg ev /die per altri 9 giorni in associazione ad idrossiclorochina 200 mg, 1 x 2 oppure x3/die con timing da stabilire secondo evoluzione clinica
+/- Tocilizumab* (richiedere dosaggio IL 6)
+/- desametasone 20 mg/die per 5 giorni poi a scalare
NB: Benché l'attuale evidenza scientifica non supporta l'uso di lopinavir/ritonavir o darunavir/cobicistat 800/150 mg 1 cp/die questi farmaci possono essere considerati nei singoli casi in fase precoce se non disponibile Remdesivir (Vedi anche nota AIFA 24/03/20).

peggioramento ↓ / miglioramento ↑

(4) Terapia intensiva ←

Se P/Fs 200 →

Paziente positivo per COVID-19 con quadro di polmonite grave, ARDS o insufficienza respiratoria globale, scompenso emodinamico, necessità di ricovero in terapia intensiva con assistenza ventilatoria meccanica
- Idrossiclorochina cp 200 mg, 1 x 2 oppure x3/die via SNG se non disponibile clorochina 500 mg, 1 x 2/ die. Durata della terapia: da 7 a 10 giorni, con timing da stabilire secondo evoluzione clinica (PS: se permanenza prevista oltre le 24 h inizia trattamento in PS). NB: Necessaria valutazione cardiologica ECG (valutazione QT) ****
- richiedere Remdesivir ad uso compassionevole. Appena disponibile: Remdesivir fiale 150 mg: 1 giorno 200 mg ev in 30 minuti poi 100 mg ev /die per altri 9 giorni in associazione ad idrossiclorochina 200 mg, 1 x 2/die con timing da stabilire secondo evoluzione clinica;
+/- Tocilizumab* (richiedere dosaggio IL 6)
+/- desametasone 20 mg/die per 5 giorni poi a scalare

*tocilizumab criteri di inclusione: Termine della fase iniziale di elevata carica virale di COVID-19 (es. apiretico da >72h e/o trascorsi almeno 7 giorni dall'esordio dei sintomi) Peggioramento degli scambi respiratori tali da richiedere supporto non invasivo o invasivo alla ventilazione (Brescia-COVID respiratory severity scale score >2) Elevati livelli di IL-6 (>40 pg/ml); in alternativa elevati livelli di d-dimero e/o PCR e/o ferritina e/o fibrinogeno in aumento progressivo.
** se disponibili ed attivi protocolli AIFA i pazienti verranno valutati per inclusione in studio clinico in via prioritaria.
***Interazioni farmacologiche e carenze di farmaci massima attenzione alle possibili interazioni farmacocinetiche. In caso di concomitante assunzione di altri farmaci utilizzare DRUG PIN https://aousa.drug-pin.com/app/
****La terapia antibiotica non è indicata, se non in presenza di indicazioni cliniche o protocolli in uso.
***** il presente protocollo, stilato dai prof.ri A. Aceti, R. Bonfini, C. Capalbo, C. Napoli, A. Ricci, M. Rocco, M. Simmaco, con il coordinamento del Direttore sanitario, Dott. P. Anibaldi, sarà oggetto di periodica verifica in funzione dell'aggiornamento dei dati di letteratura, linee guida e documenti prodotti da parte degli enti regolatori.

Anticovid:
An open access platform for global clinical trials for SARS-CoV 2 (the virus responsible for COVID-19)

This chart exhibits trial registration in the SARS-CoV-2 landscape. In general, trial registration is affected by many biases and the case of SARS-CoV-2 certainly makes no exception. Perhaps, there is even more bias given the emergency at stake, diverting researchers from ideally registering their trials in a timely and prospective manner. In any case, chart shows a recent steep increase in clinical research activity, roughly aligned with pandemic spread. The high proportion of observational studies is quite striking, as compared to what is usually observed yet it may be explained by the critical need for "trivial" data regarding this unexpected and unknown agent.

Study type
- Diagnostic test
- Interventional (study)
- Observational (study)

New trials registered each week

https://covid.inato.com/analysis

Anticovid:
An open access platform for global clinical trials for SARS-CoV 2 (the virus responsible for COVID-19)

https://covid.inato.com/analysis

References & related material

PROGNOS Technology / YouTube presentations:
  Using PROGNOS: https://www.youtube.com/watch?v=jeO_UoMsApw
  Interview on PROGNOS: https://www.youtube.com/watch?v=0MKyKzTQ3pw
  Using PROGNOS on MIR by Prof. Dr. med Valeri Vladimirovich Polyakov: https://www.youtube.com/watch?v=R4hGgJShsZU

How does COVID-19 kill?
  Therapeutic options for the 2019 novel coronavirus (2019-nCoV): https://www.nature.com/articles/d41573-020-00016-0
  Uncertainty is hampering doctors' ability to choose treatments: https://www.nature.com/articles/d41586-020-01056-7

The race for coronavirus vaccines: a graphical guide- Eight ways in which scientists hope to provide immunity to SARS-CoV-2 .
  https://www.nature.com/articles/d41586-020-01221-y?utm_source=Nature+Briefing

AntiCOVID: Clinical research for Covid-19 (by Inato): https://covid.inato.com/analysis

NIH Coronavirus Disease 2019 (COVID-19) Treatment Guidelines: https://www.covid19treatmentguidelines.nih.gov/

COHERENCE IN LIFE AND IN MATTER - Past events and related resources (in Italian): https://www.vglobale.it/?s=Coherence

Luc Montagnier (2008 Nobel Prize in Physiology or Medicine**) and Vincenzo Valenzi** (an interview in Italian and French): https://youtu.be/CuQtvjBuavI

Proceedings of COHERENCE events and related material: http://www.iiimb.me/materiali.html

COHERENCE2020 Presentations: http://www.iiimb.me/atti-di-coherence2020.html

COVID Workshop Reports: https://m.facebook.com/story.php?story_fbid=3395611340453227&id=100000131826854

4ᵗʰ MERIDIANTECH-COVID19 Workshop
Bioelectrical Diagnostics & Coherent Therapy

Controlled trials of Meridian technology-based diagnostics and diagnostics-driven precision, personalized therapy

Thursday 30 April 15:00 CEST – Hosted by MEDPREVENT systems GmbH & Co. KG DE

Giulio **TARRO** : http://www.giuliotarro.it/ , https://twitter.com/TarroGiulio & https://it.wikipedia.org/wiki/Giulio_Tarro:
Urgent need for new approaches for managing the COVID-19 pandemic

Habib **DOUAGUI:** *Professor & Head, Department of Pneumo-allergology, Center Hospitalo Universitaire de Béni Messous, Algiers,* *Algeria*

COVID-19 in Africa: The state of play and approaches to management and care

Judu **ILAVARASU:** *Division of Yoga and Physical Sciences, Swami Vivekananda Yoga Anusandhana Samsthana (SVYASA),Bangalore, India*
ACUGRAPH for COVID-19 studies: Limits and challenges

Dr. med Michael **BAUER,** Raimund **HOFFMAN** & Franziska **MICHL**: *MEDPREVENTsystems GmbH, Marktredwitz, Germany*
COVID-19 diagnostics and viral testing and assessment of organ health using the PROGNOS system

Dr. med. Thomas **RAMPP:** Faculty of Medicine, University of Duisburg-Essen & Institute for Naturopathy, Traditional Chinese and Indian Medicine, Kliniken Essen-Mitte, Essen, Germany
Visco Dendron: PROGNO-based diagnostics-driven personalised selection of 'coherent' plant preparations for therapy

Svetlana von **GRATOWSKI:** *LABORATORY OF SPECTROSCOPY AND MILLIMETER AND SUBMILLIMETER WAVE MEASUREMENTS, Kotelnikov Institute of Radioengineering and Electronics, Russian Academy of Sciences. Fryazino Branch*
Millimeter and submillimeter waves in medicine and their effects on complex biological systems

3rd MERIDIANTECH-COVID19 Workshop

Bioelectrical Diagnostics & Coherent Therapy

"Unpacking" & Understanding Meridians: Practical Measurement and Interpreting Results

Friday 23 April 18:00 CET – Hosted by MEDPREVENT systems GmbH & Co. KG DE

Raimund **HOFFMAN:** CEO, MEDPREVENT systems GmbH & Co. KG DE
INTRODUCTION: **Review and progress with MERIDIANTECH-PROGNOSNET engagements**

Judu **ILAVARASU:** Division of Yoga and Physical Sciences, Swami Vivekananda Yoga Anusandhana Samsthana (SVYASA), Bangalore, India: **ACUGRAPH studies in SVYASA, Bangalore, India.**

Dr. med Michael **BAUER,** Raimund **HOFFMAN &** Franziska **MICHL**: MEDPREVENTsystems GmbH
PROGNOS: The instrument, using the instrument, data structure, data analysis, results and interpretation

Nouri **GHARBI MD :** National Medical Coordinator, ORPEA-CLINEA, President RESPIRINTERNATIONAL, **Paris-Sud University (Paris XI)**: **COVID-19 status in France and The Maghreb: Observation and and new therapeutic strategies**

Alexander **TROFIMOV MD**: Director, International Scientific Research Institute of Cosmic Anthropoecology (ISRICA), Russia & Chief of Laboratory Helioclimatopathology of Science Center of Clinical and Experimental Medicine of Siberian Department of Russian Academy of Medical Science: Cosmico Radiations, **Solar activity and its effects on BIOLOGICAL system and and links to bacteria and viral infection susceptibility ?**

Madan **THANGAVELU** & Vincenzo **VALENZI:** www.iiimb.me
COVID-19: Challenges and opportunities for Pharmacogenomics, Pharmacoelectrodynamics & MERIDIANTech

2nd MERIDIANTECH-COVID19 Workshop

Bioelectrical Diagnostics & Coherent Therapy
A new bridge between Oriental and Occidental Medicine

Saturday 15 April 15:00 CET – Hosted by MEDPREVENT systems GmbH & Co. KG DE

Raimund **HOFFMAN**: CEO, MEDPREVENT systems GmbH & Co. KG DE
INTRODUCTION: **Why I invest all my energy and money in PROGNOS technology.**

Dr. med Michael **BAUER,** Dr med dent. Louis **NIESTEGGE** & Dr. med Beate **MAUL** (MD):
Clinical cases studied using the PROGNOS system

Antonio **ACETI** Professore Ordinario, **Sapienza University of Rome | La Sapienza**
The Rome experience with COVID-19 and possible new therapeutic strategies

Giulio **TARRO:** Chairman, Virosphere Biotechnology Committee, World Academy of Biomedical Technologies (*WABT*)–
UNESCO, Paris **The STRATEGY for tackling COVID19 using lessons of the past**

Konstantin **APYKHTIN** PhD: Institute of Gerontology, National Academy of Medical Sciences of Ukraine
Mini-ECG and HRV in home monitoring of COVID 19 patients

Madan **THANGAVELU** & Vincenzo **VALENZI:** **www.iiimb.me**
COVID-19: Challenges and opportunities for Pharmacogenomics, Pharmacoelectrodynamics & MERIDIANTech

1st PROGOSNET-COVID19 Workshop

Functional Diagnostics & Coherent Therapy
Coherent Drugs, Compatible Foods, Nutrition & Environment

Monday 13 April 16:00 – Hosted by MEDPREVENT systems GmbH & Co. KG

Raimund **HOFFMAN:**   Introduction to MEDPREVENT & PROGNOS

Madan **THANGAVELU:**   COVID-19 and the complex physiological responses of a viral infection

Vincenzo **VALENZI:**   Order and 'coherence' in complex systems and the immune system

Dr. med Michael **BAUER:**   Clinical case studies using the PROGNOS system

Jamal **AISSA, DIGIBIO, Paris:**   Low doses and high dilutions results of Benveniste and Montagnier and implications for
                COVID-19 management

Francesco **SICURELLO:**   Telemedicine systems and opportunities for the future

Prof. Antonio **ACETI:**   Experiences and lessons from COVID-19 critical care and management in Rome

                ... others to join

First they ignore you, then they laugh at you, then they fight you, then you win.

Mahatma Gandhi